Wall Street brokerages expect that American Renal Associates Holdings Inc (NYSE:ARA) will announce ($0.09) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for American Renal Associates’ earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.04). The firm is expected to issue its next quarterly earnings results on Tuesday, February 4th.

On average, analysts expect that American Renal Associates will report full year earnings of $0.03 per share for the current financial year. For the next financial year, analysts forecast that the firm will post earnings of ($0.39) per share, with EPS estimates ranging from ($0.49) to ($0.28). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover American Renal Associates.

American Renal Associates (NYSE:ARA) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.37. American Renal Associates had a negative net margin of 1.75% and a positive return on equity of 23.16%. The business had revenue of $211.43 million for the quarter, compared to the consensus estimate of $215.06 million.

A number of analysts have weighed in on the company. SunTrust Banks boosted their price target on American Renal Associates from $7.00 to $12.00 and gave the stock a “hold” rating in a research report on Tuesday, September 10th. ValuEngine lowered American Renal Associates from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. American Renal Associates presently has an average rating of “Hold” and a consensus target price of $11.25.

Shares of NYSE:ARA opened at $9.33 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.97 and a debt-to-equity ratio of 8.05. American Renal Associates has a 1 year low of $5.48 and a 1 year high of $16.86. The firm has a fifty day moving average price of $8.43 and a 200 day moving average price of $7.38.

Several institutional investors have recently bought and sold shares of the company. State Street Corp increased its position in American Renal Associates by 42.1% in the 3rd quarter. State Street Corp now owns 306,227 shares of the company’s stock worth $1,935,000 after buying an additional 90,762 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of American Renal Associates by 347.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 8,705 shares of the company’s stock worth $55,000 after purchasing an additional 6,759 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of American Renal Associates by 7.0% in the third quarter. California Public Employees Retirement System now owns 91,266 shares of the company’s stock valued at $577,000 after purchasing an additional 5,946 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in American Renal Associates during the second quarter worth $233,000. Finally, Marshall Wace LLP raised its stake in shares of American Renal Associates by 715.2% in the 2nd quarter. Marshall Wace LLP now owns 92,039 shares of the company’s stock valued at $684,000 after buying an additional 80,748 shares in the last quarter. Institutional investors and hedge funds own 85.40% of the company’s stock.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

See Also: What is a Candlestick Chart?

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.